Humana Inc.
HUM Healthcare Medical - Healthcare Plans NYSE
$179.15
$-1.60 (-0.89%)
Open: $181.46 | High: $181.46 | Low: $178.24 | Prev Close: $180.75
Market Cap: $21.60B
Volume: 959K | Avg: 1.9M
Last updated: March 09, 2026 at 02:02 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 450
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 18.37 |
| P/B Ratio | 1.22 |
| P/S Ratio | 0.17 |
| EPS | $9.75 |
| Beta | 0.42 |
| Shares Outstanding | 120.60M |
| 52-Week High | $315.35 |
| 52-Week Low | $169.61 |
| SMA 50 | $223.03 |
| SMA 200 | $249.01 |
| Dividend Yield | 1.98% |
| Annual Dividend | $3.54 |
| Next Earnings | April 29, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 14.5% |
| Operating Margin | 1.1% |
| Net Margin | 0.9% |
| ROE | 6.6% |
| ROA | 2.4% |
| Debt/Equity | 0.70 |
| Current Ratio | 2.00 |
| Quick Ratio | 2.00 |
Balance Sheet
| Total Assets | $48.91B |
| Total Liabilities | $31.17B |
| Total Equity | $17.66B |
|
|
|
| Cash | $4.20B |
| Total Debt | $12.37B |
| Net Debt | $8.17B |
Income Statement
| Revenue | $129.66B |
| Gross Profit | $18.85B |
| Operating Income | $1.45B |
| Net Income | $1.19B |
|
|
|
| EBITDA | $2.91B |
| Revenue/Share | $1077.49 |
Cash Flow
| Operating CF | $921.00M |
| CapEx | $546.00M |
| Free Cash Flow | $375.00M |
|
|
|
| Book Value/Share | $147.39 |
| Tangible Book/Share | $66.90 |
| Equity/Share | $146.73 |
Technical Indicators
| RSI (14) | 45.71 Neutral |
| MACD |
-10.68
Signal: -13.05
|
| Volatility | 71.20% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | -27.57% |
| Sharpe Ratio | -0.75 Poor |
| Volatility (Ann.) | 48.78% High Risk |
| HUM (1Y) | -27.57% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -40.6% |
Sector Comparison (Healthcare)
| Metric | HUM | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 18.37 | 27.83 | 28% |
| P/B Ratio | 1.22 | -19.55 | 15% |
| ROE (%) | 6.59% | -9.41% | 25% |
| Net Margin (%) | 0.92% | 9.48% | 13% |
| Stock Score | 450 | 545.0 | 13% |
| 1Y Return (%) | -27.57 % | +8.84 % | 10% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HUM | $179.15 | $181.23 | $181.75 | $182.88 | $223.13 | $249.03 | 45.71 | -10.68 | 71.20% | 245970 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the HUM stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| HUM | Why Is Humana (HUM) Down 8.5% Since Last Earnings Report? | Neutral | zacks.com | Read More |
| HUM | Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes | Positive | businesswire.com | Read More |
| HUM | 4 HMO Stocks to Watch Despite Escalating Costs, Nursing Shortage | Neutral | zacks.com | Read More |
| HUM | Capital Group Private Client Services Inc. Purchases Shares of 8,545 Humana Inc. $HUM | Neutral | defenseworld.net | Read More |
| HUM | Humana Inc. (HUM) Presents at Leerink Global Healthcare Conference 2026 Transcript | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for HUM
Company Information
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
| CEO | James A. Rechtin |
| Employees | 65680 |
| Country | US |
| IPO Date | 1981-12-31 |
| Exchange | NYSE |
| Website | https://www.humana.com |
| Sector | Healthcare |
| Industry | Medical - Healthcare Plans |
Similar Stocks (Healthcare - Medical - Healthcare Plans)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category